seems to have found a floor, page-16

Thanks for the heads up on that research report taxing.

This makes clear what management have been saying about the "rate away loss" being highly statistically significant (99%+).

Also, while it seems a little strange that the most effective dose is the lowest, this appears to be the nature of the HGH beast. That the 1 mg dose was most effective was apparently expected after the animal studies - I think I remember management saying something to this effect when I called them.

There is one thing for sure, if it works without side effects then there is no way this drug can be anything but a blockbuster. Any rumour of a deal will send the SP ballistic.

Whoever it was that paid $2.50 on the morning of the trial result release was betting the drug would be worth multiples of this price, and for good reason.

My wife expressed immediate interest in taking this drug. Skinny fashion models in magazines and women's vanity make robust sales all but completely bankable. And then there's the growth in obesity in western countries that bodes well for sales growth.

It really is just a case of wether the drug works, if it does then MBP is clearly very much undervalued.

I'm becoming very much more bullish.

The bet is, I guess, that these guys at Cohen Research know their stuff. I think I might pick up some more MBP on Monday if it doesn't move up too quickly.

Again, thanks for the heads up on the research report taxing.

Zoot

Do your own research and due diligence.